News

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer (mCRC) whose tumors are microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR)—a population with a historically poor prognosis, said Heinz-Josef Lenz, MD, FACP.

Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.

Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.

There are multiple steps nurses must take to prevent and manage pulmonary toxicities in patients taking immunotherapy.

Two different randomized clinical trials not only validated the value of annual lung cancer screening in patients, but also can open the doors for vital smoking cessation talks.

The Centers for Medicare and Medicaid Services (CMS) announced that it will cover chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Save the date! We invite you to join Oncology Nursing News for an #OncNurseConnect Tweet Chat on Wednesday, August 21.

This is the first approval for this patient population in nearly a decade.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Oncology nurses can make the world of a difference when it comes to patient care, and it is crucial that they work together with other members of the treatment team to ensure the best outcomes, according to Sally Werner, MSHA, BSN, RN, senior vice president, affiliate relations at Cancer Support Community.

Workplace violence for healthcare workers – including nurses – is on the rise. Here’s what nurses need to know about the hot-button topic.

Hair, skin, or nail reactions commonly occur in patients treated with immunotherapy and targeted therapy for cancer.

PARP inhibitors have shown success in breast and ovarian cancer, and now they may be moving into the pancreatic cancer paradigm, too.

Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.

The Food and Drug Administration (FDA) approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT).

About 25% of healthcare-related infections come from catheters, but there are steps nurses can take to mitigate this problem.

Here are the top 5 Oncology Nursing News stories for July 2019.

The FDA approved pembrolizumab to treat certain patients with recurrent, locally advanced or metastatic squamous cell carcinoma of the esophagus.

The FDA has approved darolutamide (Nubeqa) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The annual SONO meeting will feature the latest research and pressing topics for oncology nurses.

One expert discusses the arrival of immunotherapy, as well as other exciting advances, for the treatment of patients with small cell lung cancer.

Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).

Several key abstracts presented at the 2019 ASCO Annual Meeting demonstrated practice-changing potential in the prostate cancer field, said Celestia S. Higano, MD, FACP.

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.

Many adolescent and young adult cancer survivors struggle in the post-cancer period. Oncology nurses can help ensure that they don’t fall through the cracks.

The Food and Drug Administration granted a priority review for a new drug application for tazemetostat. The drug will be used to treat a rare kind of soft tissue sarcoma that mainly affects young adults.

After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.

Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.